Medtronic (MDT) Expected to Announce Earnings on Tuesday

Medtronic (NYSE:MDT) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, November 18th. Analysts expect the company to announce earnings of $1.31 per share and revenue of $8.8561 billion for the quarter. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.Parties may visit the the company’s upcoming Q2 2026 earningresults page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 8:00 AM ET.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same period last year, the company earned $1.23 earnings per share. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Stock Performance

Shares of MDT opened at $95.92 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic has a 1 year low of $79.29 and a 1 year high of $99.37. The firm has a fifty day moving average of $94.43 and a 200-day moving average of $90.39. The company has a market cap of $123.04 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. 0.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MDT. Brighton Jones LLC lifted its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC raised its position in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the last quarter. Jump Financial LLC acquired a new position in Medtronic in the second quarter worth $299,000. Main Street Financial Solutions LLC grew its holdings in shares of Medtronic by 28.9% during the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after purchasing an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its stake in shares of Medtronic by 21.3% in the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after buying an additional 3,376 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MDT has been the subject of several recent analyst reports. Argus increased their price target on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. UBS Group boosted their target price on Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday. JPMorgan Chase & Co. increased their price target on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $103.06.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.